Asarina Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Asarina Pharma
Access all reports
Asarina Pharma AB is a Swedish biotechnology company specializing in the development of Sepranolone, a compound designed to treat stress, compulsivity, and neurological disorders related to Allopregnanolone. This neurosteroid is implicated in conditions such as Tourette syndrome, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). Asarina Pharma's focus is on innovative treatments that modulate the effects of Allopregnanolone, aiming to provide safer and more effective therapeutic options. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ASAP
Country
🇸🇪 Sweden